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ISSObjectives: In the absence of HIV-1 virion infectivity factor (Vif), cellular cytosine
deaminases such as apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like
3G (APOBEC3G) inhibit the virus by inducing hypermutations on viral DNA, among
other mechanisms of action. We investigated the association of APOBEC3G mRNA
levels and genetic variants on HIV-1 susceptibility, and early disease pathogenesis using
viral load and CD4þ T-cell counts as outcomes.
Methods: Study participants were 250 South African women at high risk for HIV-1
subtype C infection. We used real-time PCR to measure the expression of APOBEC3G in
HIV-negative and HIV-positive primary infection samples. APOBEC3G variants were
identified by DNA re-sequencing and TaqMan genotyping.
Results: We found no correlation between APOBEC3G expression levels and plasma
viral loads (r¼0.053, P¼0.596) or CD4þ T-cell counts (r¼0.030, P¼0.762) in 32
seroconverters. APOBEC3G expression levels were higher in HIV-negative individuals
as compared with HIV-positive individuals (P<0.0001), including matched pre and
postinfection samples from the same individuals (n¼13, P<0.0001). Twenty-four
single nucleotide polymorphisms, including eight novel, were identified within APO-
BEC3G by re-sequencing and genotyping. The H186R mutation, a codon-changing
variant in exon 4, and a 30 extragenic mutation (rs35228531) were associated with high
viral loads (P¼0.0097 and P<0.0001) and decreased CD4þ T-cell levels (P¼0.0081
and P<0.0001), respectively.
Conclusion: These data suggest that APOBEC3G transcription is rapidly downregulated
upon HIV-1 infection. During primary infection, APOBEC3G expression levels in
peripheral blood mononuclear cells do not correlate with viral loads or CD4þ T-cell
counts. Genetic variation of APOBEC3G may significantly affect early HIV-1 patho-
genesis, although the mechanism remains unclear and warrants further investigation.
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Apolipoprotein B mRNA-editing enzyme catalytic
polypeptide-like 3G (APOBEC3G), a human cytidine
deaminase, has potent antiviral activity [1–4], and its
polymorphic variants may modulate resistance to infec-
tion or disease progression among those infected [5]. In
the absence of the HIV-1 accessory protein, virion
infectivity factor (Vif), APOBEC3G, is packaged into
budding virions, and subsequently deaminates dC to dU
in the retroviral minus strand reverse transcripts in target
cells. These substitutions register as dG (guanidine) to dA
(adenine) transitions in retroviral plus stranded DNA [6].
Excessive G-to-A substitutions, known as hypermuta-
tion, are common among lentiviruses and introduce
multiple termination codons across their genomes [6–9].
APOBEC3G and other cytidine deaminases may also
inactivate lentiviruses by other mechanisms apart from
hypermutation [10,11]. Hypermutated viral sequences
have been identified in long-term nonprogressors and
were predominant over time, suggesting that cytidine
deaminases may play a role in viral control in vivo [12,13].
HIV-1 Vif counteracts APOBEC3G by blocking its
encapsulation into virions, targeting the host protein to
the ubiquitin pathway for proteasome-mediated degra-
dation, resulting in the eradication of APOBEC3G and
the loss of its anti-HIV activity [14–19].
Increased expression of APOBEC3G may overcome the
effects of Vif by providing a competitive advantage over
time and may eventually incapacitate the virus and
suppress viremia [20]. Additionally, genetic variants of
APOBEC3G may alter its function or level of expression,
thereby enhancing or diminishing its anti-HIV activity
[21–23].
Given that APOBEC3G is a key intrinsic antiretroviral
host factor that possesses significant anti-HIV-1 activity in
vitro, we reasoned that its antiviral effects in vivo might be
particularly pronounced during the primary infection
phase before adaptive immune responses become
established. We therefore, investigated the hypothesis
that high mRNA levels of APOBEC3G in peripheral
blood mononuclear cells (PBMCs) of seroconverters are
associated with low viral setpoint and high CD4þ T-cell
counts during primary HIV-1 subtype C (HIV-1C)
infection. We also investigated the effects of APOBEC3G
genetic polymorphisms on HIV-1C pathogenesis in a
South African cohort, in a population where the HIV-1
epidemic is severest.Participants and methods
Study participants
The Centre for the AIDS Programme of Research In
South Africa (CAPRISA) acute infection study [24] is anpyright © Lippincott Williams & Wilkins. Unauthorobservational natural history study of HIV-1C infection
established in Durban, South Africa, in 2004. Two
hundred and forty-five women at high risk for HIV
infection were enrolled into phase 1 of the study.
Participants were screened monthly and seroconverters
were identified by two HIV-1 rapid antibody tests,
Determine (Abbott Laboratories, Tokyo, Japan) and
Capillus (Trinity Biotech, Jamestown, New York, USA).
Antibody-negative samples underwent pooled PCR
testing for HIV-1 RNA (Ampliscreen v1.5; Roche
Diagnostics, Rotkreuz, Switzerland). HIV-1 RNA-
positive samples were subsequently confirmed by
quantitative RNA (Amplicor v2.0; Roche Diagnostics)
and HIV enzyme immunoassay test (BEP 2000; Dade
Behring, Marburg, Germany). Participants with acute
HIV infection and those from other seroincidence
cohorts were recruited into phase 2 on the basis of a
reactive HIV antibody test within 3 months of a
previously negative result or PCR positive in the absence
of antibodies. The estimated time of seroconversion was
determined as the midpoint between the last antibody-
negative and first antibody-positive test or 14 days before
the participant was PCR positive and antibody negative.
Acutely infected participants are followed weekly for 3
weeks, fortnightly until 3 months after infection, monthly
until 12months after infection and thereafter quarterly for a
maximum of 5.5 years. A flow diagram summarizing the
study cohort and experiments is available in Fig. 1. Ethical
approval was obtained from the University of KwaZulu-
Natal’s Biomedical Research Ethics Committee and all
participants provided written informed consent.
Sample collection, measurement of CD4 cell
counts and plasma viral load
Blood was obtained by venipuncture and PBMCs were
isolated by Ficoll–Histopaque (Sigma, St Louis, Missouri,
USA) density gradient centrifugation and frozen until
use. Viral load was determined using the automated
COBAS AMPLICOR HIV-1 Monitor Test v1.5 (Roche
Diagnostics). CD4 cells were enumerated by using the
Multitest kit (CD4/CD3/CD8/CD45) on a four-
parameter FACS Calibur flow cytometer (Becton
Dickinson, Franklin Lakes, New Jersey, USA).
mRNA expression analysis
APOBEC3G mRNA expression was quantified in 30
HIV-negative participants and in longitudinal samples of
32 HIV-positive participants. Additionally, 13 of the 32
HIV-positive participants had preinfection (baseline)
samples available. RNA was isolated from cryopreserved
PBMCs immediately after thawing using Trizol reagent
(Invitrogen, Carlsbad, California, USA) according to the
manufacturer’s protocol. RNA was reverse transcribed to
synthesize cDNA using the Quantitect Reverse Tran-
scription Kit (Qiagen, Venlo, The Netherlands).
APOBEC3G mRNA expression was quantified by real-
time PCR using SYBR Green chemistry (Rocheized reproduction of this article is prohibited.
C




HIV risk behaviour assessment,
clinical evaluation, blood collection
for routine lab assessment, HIV
status and STI’s
Clinical evaluation, 2 HIV antibody

















52 +ve58 +ve61 +ve
H186R rs6001417 rs35228531
37 +ve30 +ve32 +ve 30 −ve 30 −ve 131 −ve








Fig. 1. Outline of study cohort and experiments. HIV-positive samples are indicated by pink blocks and HIV-negative samples are
indicated by blue blocks.Diagnostics). Target-specific primers, used to amplify
APOBEC3G, were previously published [20]. The
housekeeping gene, glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (NM_002046), was used to normalize
for variations in cell count or differences in nucleic acid
extraction. GAPDH primers were: forward, 50-
AAGGTCGGAGTCAACGGATT-30 (nucleotides 115–
134); reverse, 50-CTCCTGGAAGATGGTGATGG-30
(nucleotides 320–339). Each optimized 10 ml PCR
reaction contained 1–2 ml of 25 mmol/l MgCl2 (primer
set dependent), 1 ml of 10 LightCycler FastStart DNA
Master SYBR Green I (Roche Diagnostics), 0.2 ml of each
10 mmol/l APOBEC3G primer or 0.5 ml of each
10 mmol/l GAPDH primer and 2 ml of complementary
DNA (cDNA) template. Reactions were run on the
LightCycler Instrument Version 1.5 (Roche Diagnostics).
PCR cycling conditions were one cycle at 958C for
10 min, 40 cycles of 958C for 5 s, 558C (APOBEC3G) or
658C (GAPDH) for 15 s and 728C for 5 s. Standard curves
were generated for APOBEC3G and GAPDH from 10-
fold serial dilutions of cDNA of known concentration.
Standard curveswere imported into each PCR run and was
used by LightCycler software (Roche Diagnostics) to
quantify each gene in a sample by extrapolation. Samples
and standardswere run in duplicate and average values were
used to compute APOBEC3G and GAPDH copyopyright © Lippincott Williams & Wilkins. Unauthnumber. Relative expression levels of APOBEC3G to
GAPDH in each sample were determined by dividing the
concentration of APOBEC3G by the concentration of
GAPDH.
Detection of APOBEC3G polymorphisms
A DNA panel of 30 HIV-positive and 30 HIV-negative
samples was resequenced to identify single-nucleotide
polymorphisms (SNPs) in APOBEC3G. Sequencing
primers and protocols used were previously published
[22]. Primers covered the putative 50 regulatory region,
eight exons, exon–intron junctions, intron 1 and the 30
untranslated region of the APOBEC3G gene (GenBank
sequences AL022318 and AL078641). These regions
were amplified separately. Each 25 ml PCR reaction
contained 10 PCR buffer, 1.5 or 2.5 mmol/l MgCl2
(primer set dependent), 2.4 mmol/l deoxynucleoside
triphosphate mix, 0.15 ml TaqGold and 5 mmol/l of each
forward and reverse primer. This was amplified at 958C
for 10 min, 35 cycles of 948C for 30 s, 608C for 30 s, 728C
for 45 s and a final 10-min extension step at 728C. PCR
products were purified using exonuclease and shrimp
alkaline phosphatase (Amersham Pharmacia, Uppsala,
Sweden) and sequenced using overlapping primers and a
BigDye Terminator Kit (Applied Biosystems, Foster City,
California, USA). Sequencing primers, regions amplifiedorized reproduction of this article is prohibited.
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198 AIDS 2010, Vol 24 No 2and PCR conditions are available in supplementary
material (Table S1).
Genotyping of variants
Five SNPs, identified by resequencing APOBEC3G, were
further genotyped in 168 samples (37 HIV-positive and
131 HIV-negative). TaqMan SNP genotyping assays and
PCR restriction fragment length polymorphism (RFLP)
were used to determine genotypes for these polymorph-
isms. TaqMan assays were carried out according to the
manufacturer’s protocol (Applied Biosystems). PCR
primers, conditions and restriction enzymes used for the
RFLP assay and details of TaqMan genotyping assays are
available in supplementary material (Table S2). After
preliminary statistical analysis, the H186R, rs6001417 and
rs35228531 SNPs were selected for further genotyping on
the basis of their strong association with viral load and CD4
cell count. H186R was genotyped in 250 samples (61 HIV-
positive and 189 HIV-negative), rs6001417 was genotyped
in 246 samples (58 HIV-positive and 188 HIV-negative)
and rs35228531 was genotyped in 220 samples (52 HIV-
positive and 168 HIV-negative).
Statistical analysis
APOBEC3G mRNA expression levels were compared
between HIV-negative and HIV-positive individuals
using a generalized estimating equation (GEE) model
[25–27]. This analysis takes into account longitudinal
(repeated) measures for each participant. The association
between APOBEC3G mRNA levels and viral loads and
CD4 cell counts was determined using rank correlation
tests. Fisher’s exact test was used to test the association
between HIV status and H186R (rs8177832), rs6001417
and rs35228531 genotypes. The genetic effects of these
mutations on viral loads and CD4 cell counts were also
determined by a GEE model taking into account
longitudinal measures for each participant. The data
were represented by a locally weighted scatterplot
smoothing model, which was used to plot smooth curves
over the data points. A Kaplan–Meier survival analysis
was performed to assess the difference in CD4 decline
between the H186R, rs6001417 and rs35228531
genotype groups, and Cox regression was used to acquire
hazard ratios. All statistical analysis was performed using
SAS version 9.1 (SAS Institute, Cary, North Carolina,
USA) and graphs were generated using GraphPad Prism
version 5.01 for Windows (GraphPad Software, San
Diego, California, USA).Results
APOBEC3G expression
There is paucity of data regarding the interplay between
HIV-1 and APOBEC3G expression in vivo, particularly,
during primary infection when rapid viral replication
occurs, followed by resolution of viremia and establish-pyright © Lippincott Williams & Wilkins. Unauthorment of steady-state equilibrium between the virus and
the body’s immune responses. We therefore, investigated
whether primary HIV-1C infection is associated with
changes of APOBEC3G expression in PBMCs as
compared with HIV-negative samples. Comparison of
APOBEC3G mRNA levels between HIV-negative and
HIV-positive individuals within 12 months of infection
(primary infection) showed that APOBEC3G levels were
significantly higher in HIV-negative individuals than in
HIV-positive individuals (P< 0.0001) (Fig. 2a).
Additionally, comparison of APOBEC3G expression
levels in matched pre and postinfection samples of
seroconverters also showed that APOBEC3G expression
was significantly higher before seroconversion
(P< 0.0001) (Fig. 2b). Further, there was no significant
difference in APOBEC3G levels when compared
between individuals who are persistently seronegative
and preinfection samples of seroconverters (Fig. 2c).
Comparison of APOBEC3G mRNA levels at various
time points after infection (Fig. 2d) showed no significant
change in expression levels over time.
There is conflicting data on the relationship between
APOBEC3G mRNA levels in PBMCs versus plasma
viral load and CD4 cell counts in chronic HIV-1 infection
[20,28,29]. We thus next investigated whether there is a
correlation between APOBEC3G mRNA levels and
HIV-1 plasma viral load and CD4 cell counts during
primary HIV-1 infection and found no association
between these factors (data not shown).
APOBEC3G variants
APOBEC3G genetic variants have not been described in
African populations. By resequencing and genotyping,
we identified 24 SNPs within APOBEC3G in our cohort
(Table 1). Sixteen of these SNPs were described
previously and eight were novel. Further, An et al. [22]
described seven SNPs within APOBEC3G in a USA-
based study cohort, four of which were identified in our
study cohort. Frequencies of these SNPs in our cohort
were similar to those of the African–American group in
the USA-based cohort (Table 1).
The codon-changing variant, H186R (rs8177832), in
exon 4, had a frequency of 0.307 and was analyzed
further, as the 186R allelle was previously shown to have
AIDS-accelerating effects [22]. Two other APOBEC3G
variants, rs6001417 in intron 3 and rs35228531, an
extragenic mutation located 30 near the gene, having
allele frequencies of 0.303 and 0.207, respectively, were
also further analyzed after preliminary analysis indicated
that they also had AIDS-accelerating effects.
Effects of H186R, rs6001417 and rs35228531
mutations on primary HIV pathogenesis
H186R genotypes were determined for 250 individuals
(61 HIV-positive and 189 HIV-negative). We tested the
association between HIV status and H186R genotypesized reproduction of this article is prohibited.
C
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Fig. 2. Comparison of APOBEC3G mRNA levels between (a) HIV-uninfected and HIV-infected participants, (b) preinfection and
postinfection samples of HIV-infected individuals, (c) persistently seronegative individuals and preinfection samples of
seroconverters and (d) longitudinal postinfection samples. In (b), the postinfection column represents postinfection samples
from three time points for each individual. These time points are at 3, 6 and 12 months after infection. A generalized estimating
equation analysis model was used to analyze these data, as this model takes into account longitudinal (repeated) measures for each
participant.and found no significant difference in the distribution of
H186R genotypes between HIV-negative and HIV-
positive individuals (P¼ 0.5838) (data not shown).
We also compared viral loads (Fig. 3a) and CD4þ T-cell
counts (Fig. 3b) between genotypes. Viral load and CD4
measurements were classified into 0–3 months after
infection and 3–12 months after infection time intervals to
identify possible differences between genotypes during
acute infection (0–3 months) and early chronic infection
(3–12 months). There was an overall significant difference
in viral loads between genotypes (P¼ 0.0097) across both
time periods (Fig. 3a). In addition, during the first 3
months of infection, there was a significant difference in
viral loads between the wild-type reference group (AA)
and those homozygous for the mutation (GG)
(P¼ 0.0362), with the GG genotype having higher viral
loads than the AA genotype. There was also an overall
significant difference in CD4 cell counts between the AAopyright © Lippincott Williams & Wilkins. Unauthreference group and the GG genotypes (P¼ 0.0081)
(Fig. 3b). Further, during the first 3 months of infection,
there was a significant difference in CD4 cell counts
between AA and GG genotypes (P¼ 0.0006), with GG
genotype having lower CD4 cell counts than the AA
genotype. The association with CD4þ T-cell count is
consistent with observed genotype effects on viral load. At
3–12 months after infection, the GG genotype maintained
its association with higher viral loads and lower CD4 cell
counts when compared with the other genotypes.
Additionally, the heterozygous AG genotype also displays
significantly higher viral loads (P¼ 0.0005) and lowerCD4
cell counts (P¼ 0.0078)whencomparedwith thereference
AA genotype at this later time period. Kaplan–Meier
survival analysis (Fig. 3c) shows that thosewho have the GG
genotype have a significantly shorter time to CD4 cell
count less than 350 cells/ml. The hazard ratio for the GG
group as compared with the AA or AG group is 3.84 [95%
confidence interval (CI) 1.43–10.35, P¼ 0.0078].orized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
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202 AIDS 2010, Vol 24 No 2In addition, we tested the association of the rs6001417
mutation with HIV status, CD4 cell count and viral load
(data not shown). This polymorphism was in near-perfect
linkage disequilibrium with H186R, had no significant
association with HIV status but the mutant genotype
(GG) was associated with significantly higher viral loads
and lower CD4 cell counts (P< 0.0001).
Analysis of the rs35228531 mutation indicated that
individuals who are heterozygous for the mutation (CT)
had significantly higher viral loads and lower CD4 levels
over 12 months of infection as compared with the wild-
type group (Fig. 3d and e). A Kaplan–Meier survival
analysis (Fig. 3f) shows that those who have the CT
genotype progress faster to a CD4 cell count below
350 cells/ml. The hazard ratio for the CT group as
compared with the CC group is 2.28 (95% CI 0.85–6.07,
P¼ 0.1005). Although this was not statistically signifi-
cant, a trend is observable, as only 22.9% of the CC group
progressed to a CD4 cell count below 350 cells/ml,
whereas 47.1% of individuals with the CT genotype
progressed to a CD4 cell count below 350 cells/ml.Discussion
In this study, we were interested in describing the
contribution of APOBEC3G to viral control during the
critical primary infection phase, as well as understanding
the kinetics of APOBEC3G expression before and after
infection. Early HIV-1 infection has been associated with
immobilization or profound dysregulation of antiviral
immune responses [30,31]. Therefore, it is unclear
whether HIV-1 infection would result in mobilization
or dysregulation of intrinsic immunity factors such as
APOBEC3G, which appear to be a key component of
innate immunity. We hypothesized that at the critical
phase of primary HIV-1 infection, APOBEC3G expres-
sion levels might correlate negatively with viremia and
positively with CD4þ T-cell counts.
Our data show that APOBEC3G mRNA levels are lower
in HIV-positive primary infection PBMCs as compared
with HIV-negative PBMCs. Furthermore, in matched
pre and postinfection samples of seroconverters, APO-
BEC3G mRNA levels declined, suggesting a dysregula-
tion of APOBEC3G mRNA during primary HIV-1
infection. Thus, our results are consistent with most of
the earlier studies [20,28,29,32] showing that APO-
BEC3G expression levels were higher in HIV-uninfected
individuals when compared with HIV-infected individ-
uals, although contrary findings have also been reported
[33]. Our study extends the findings from the earlier
studies to the primary HIV-1 infection phase. We also
show that in matched pre and postinfection samples,
APOBEC3G levels declined, suggesting an active
mechanism of APOBEC3G dysregulation rather thanpyright © Lippincott Williams & Wilkins. Unauthorincreased susceptibility to infection among those with
low baseline (preinfection) levels of APOBEC3G. We
found no significant differences in preinfection APO-
BEC3G mRNA levels between seroconverters and
nonseroconverters followed longitudinally, suggesting
that APOBEC3G mRNA levels per se are not associated
with protection against HIV-1 infection.
Our results, therefore, lend support to previous
observations that HIV-1 has specific mechanisms for
counteracting APOBEC3G as a possible immune evasion
strategy. We cannot also rule out the possibility that HIV-
1 infection is associated with redistribution away from
peripheral blood of cellular components that are enriched
for APOBEC3G or that HIV-1 specifically targets such
cells. Further studies will be needed to address how
APOBEC levels change in different cell subsets following
infection. Recent data from HIV-1-uninfected individ-
uals reveal that APOBEC3G is broadly expressed in
different hematopoietic subsets and that mRNA levels
may not always be concordant with protein levels [34].
Thus future studies will need to address expression at both
mRNA and protein levels in HIV-positive individuals.
Studies show that immune evasion against APOBEC3G is
mediated by HIV-1 Vif, and that it is two-fold, involving
translational and posttranslational inhibitory effects on
APOBEC3G [17]. There have been no previous reports
showing that HIV-1 inhibits APOBEC3G expression at
the transcriptional level. Whether the APOBEC3G
mRNA reduction seen in HIV-positive samples in this
study is tied to or independent of ubiquitin proteasome
degradation mediated via HIV-1 Vif may require further
investigation, but our results suggest that a third mode of
HIV-1 APOBEC3G inhibition may involve downregula-
tion of mRNA expression. This observation is in contrast
to in-vitro studies in which HIV-1 infection does not
appear to affect APOBEC3G mRNA levels [17,35,36]. In
agreement with two previous studies [28,29] performed in
chronically infected patients, we found no correlation
between APOBEC3G mRNA levels and viral load or
CD4 cell counts in this primary infection cohort. In one
study [20] that found a significant inverse correlation
between APOBEC3G mRNA levels and viral load and a
positive correlation with CD4þ T-cell count, the
investigators stimulated PBMCs with antibodies before
RNA isolation, which may explain their contrary findings.
We also investigated the extent of genetic variation within
APOBEC3G in a South African study cohort in which
HIV-1C predominates. Sub-Saharan Africa is worst
affected by the HIV-1 epidemic, and despite this situation,
relatively few studies [5,22,37] have attempted to define
genes that may affect HIV/AIDS outcomes in the local
populations and yet their frequencies may vary according
to ethnic background. In this cohort, we describe the
frequencies of several SNPs and identify several novel
SNPs that have not been described before.ized reproduction of this article is prohibited.
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APOBEC3G, the H186R mutation, is associated with an
AIDS-accelerating effect in African–Americans infected
with HIV-1B [22]. This mutation, which occurred at a
frequency of approximately 30% in our HIV-1C-
infected African cohort, was associated with significantly
increased viral loads and decreased CD4þ T-cell counts,
consistent with the earlier findings. The rs6001417
mutation is in linkage disequilibrium with H186R and,
therefore, showed highly similar associations. The
detrimental effects of this mutation are, therefore,
observable during primary infection and become more
prominent with progression to early chronic infection. It
remains unclear how this polymorphism may affect the
antiviral activity of APOBEC3G [22,23,38,39], and our
findings emphasize the need for further studies to address
the possible mechanisms.
Our data, however, indicate that this SNP is out of
Hardy–Weinberg equilibrium (HWE) (P¼ 0.04) in our
study population. We have eliminated genotyping error as
a reason for this, as we have both resequencing and
TaqMan genotyping confirmation. Further, genotypes
that were obtained were consistent between duplicates
and free of contamination, as negative controls did not
amplify. When HWE was calculated separately for HIV-
positive and HIV-negative individuals, we found that the
HIV-positive group conformed to HWE (P> 0.05),
whereas individuals in the HIV-negative group were out
of HWE (P¼ 0.03). Therefore, the distortion seems to be
due to the excess of the GG genotype in the negative
group (26/31), which may suggest that the minor allele is
protective against infection in homozygotes, although this
was not significant in our cohort (odds ratio¼ 0.54,
P¼ 0.23) using the AA as the reference group. This may
be the reason for the distortion in HWE in the negative
group in which we see an excess of GG genotypes. This
suggests that this mutation may reduce susceptibility to
HIV infection, but upon infection becomes detrimental
and accelerates disease progression. A larger sample size
will be required to resolve this issue.
Further, the rs35228531 mutation, which occurred at an
allele frequency of approximately 20% in our cohort, was
associated with significantly high viral loads and low CD4
cell counts. This mutation, however, is extragenic,
located 30 near the gene and may, therefore, affect
transcriptional regulation or posttranscriptional modifi-
cations of this antiviral factor.Conclusion
Wehave shownthatHIV-1 infection is associatedwith rapid
downregulation of APOBEC3G expression at the tran-
scriptional level. Studies to decipher the mechanisms
involved and to possibly develop means for counteractingopyright © Lippincott Williams & Wilkins. Unauththis are needed. During primary infection, APOBEC3G
expression levels inPBMCsdonot correlatewithviral loads
or CD4þT-cell counts. Importantly, this is the first study to
describe APOBEC3G genetic polymorphisms in an
African setting, where HIV-1C prevalence and incidence
rates are extremely high. This is the first study that indicates
that APOBEC3G may be an important HIV/AIDS-
modifying gene during primary HIV-1 infection. Genetic
variants of APOBEC3G significantly affect early and late
HIV-1 pathogenesis, although the mechanism remains
unclear and warrants further investigation.Acknowledgements
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Table S1. PCR sequencing primers, regions amplified and PCR conditions.
Primer Name Amplified Regions Forward primer Reverse primer T (8C) Mgþþ
CEM15-Ex1 Exon 1, intron 1, exon 2, intron 2 gacggaatttcgctcttgtc gggagagaaggacacactgg 60 1.5
CEM15-Ex3 Exon 3, Intron 3, exon 4, intron 4 ggtgagaagtgggaggttca gacctggtctggaacagagg 60 1.5
CEM15-Ex4 Intron 4, exon 5 aggtttggaggctctagcaa cactgaagccgaagtctcc 60 1.5
CEM15-Ex5 Exon 5, Intron 5, exon 6, intron 6 cctcatggcttgctttcttt gtcgaccccaaagtcaggt 60 1.5
CEM15-Ex6 Intron 6, exon 7, intron 7, gctggaagtggaagcagaac agtgacaatgatcggagagga 60 1.5
CEM15-In12 Intron 2 ctgcgtgggtcacgtaca gcctcgtgtgtgaattctagc 60 1.5
CEM15-In13 Intron 2, exon 3, intron 3 gctgggaaaacttccaaactc tttccctccatccccctgt 60 1.5
CEM15-pm1 5’ region, exon 1 acgcctggccatttactct aagtgaggcttcatccttgg 60 2.5
CEM15-pm2 5’ region ctcctcctgtagcctgttcaa gacagggagggagagtaa 60 1.5
CEM15-pm3 5’ region ggcggtggaaagttacagtc tttagaagcaggaggggttg 60 2.5
CEM15-3U Intron 7, exon 8, 3’ region cctcctctccgatcattgtc cctcctctccgatcattgtc 60 1.5
Table S2. PCR primers, PCR conditions and restriction enzymes used for the RFLP assay, and details of TaqMan Genotyping Assays.
NCBI dbSNP ID Method Forward primer Reverse primer T (8C) Mgþþ Enzyme
rs5750743 RFLP acgcctggccatttactct gccctccctaaagtgacctc 62 2.0 AvaI
NCBI dbSNP ID Method ABI Assay ID
rs8177832 TaqMan Assay C_2189646_10
rs17496046 TaqMan Assay C_25649193_10
rs6001417 TaqMan Assay C_30089175_10
rs3736685 TaqMan Assay C_27489853_10
rs35228531 TaqMan Assay C_61215563_10opyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
